179 related articles for article (PubMed ID: 33015525)
1. Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer.
Wise DR; Schneider JA; Armenia J; Febles VA; McLaughlin B; Brennan R; Thoren KL; Abida W; Sfanos KS; De Marzo AM; Yegnasubramanian S; Fox JJ; Haas M; Heath H; Kagey MH; Newman W; Sirard CA; Fleisher M; Morris MJ; Chen Y; Larson SM; Haffner MC; Nelson PS; Schultz N; Garabedian MJ; Scher HI; Logan SK; Sawyers CL;
JCO Precis Oncol; 2020; 4():. PubMed ID: 33015525
[TBL] [Abstract][Full Text] [Related]
2. A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Wise DR; Pachynski RK; Denmeade SR; Aggarwal RR; Deng J; Febles VA; Balar AV; Economides MP; Loomis C; Selvaraj S; Haas M; Kagey MH; Newman W; Baum J; Troxel AB; Griglun S; Leis D; Yang N; Aranchiy V; Machado S; Waalkes E; Gargano G; Soamchand N; Puranik A; Chattopadhyay P; Fedal E; Deng FM; Ren Q; Chiriboga L; Melamed J; Sirard CA; Wong KK
Prostate Cancer Prostatic Dis; 2024 Feb; ():. PubMed ID: 38341461
[TBL] [Abstract][Full Text] [Related]
3. Dickkopf-1 (DKK1) drives growth and metastases in castration-resistant prostate cancer.
Rinella L; Fiorentino G; Compagno M; Grange C; Cedrino M; Marano F; Bosco O; Vissio E; Delsedime L; D'Amelio P; Bussolati B; Arvat E; Catalano MG
Cancer Gene Ther; 2024 May; ():. PubMed ID: 38740881
[TBL] [Abstract][Full Text] [Related]
4. CD38 in Advanced Prostate Cancers.
Guo C; Crespo M; Gurel B; Dolling D; Rekowski J; Sharp A; Petremolo A; Sumanasuriya S; Rodrigues DN; Ferreira A; Pereira R; Figueiredo I; Mehra N; Lambros MBK; Neeb A; Gil V; Seed G; Terstappen L; Alimonti A; Drake CG; Yuan W; de Bono JS;
Eur Urol; 2021 Jun; 79(6):736-746. PubMed ID: 33678520
[TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving
Kessel K; Seifert R; Weckesser M; Roll W; Humberg V; Schlack K; Bögemann M; Bernemann C; Rahbar K
Theranostics; 2020; 10(17):7645-7655. PubMed ID: 32685010
[No Abstract] [Full Text] [Related]
6. Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer.
Betella I; Turbitt WJ; Szul T; Wu B; Martinez A; Katre A; Wall JA; Norian L; Birrer MJ; Arend R
Gynecol Oncol; 2020 Jun; 157(3):765-774. PubMed ID: 32192732
[TBL] [Abstract][Full Text] [Related]
7. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
[TBL] [Abstract][Full Text] [Related]
8. A prostate cancer gastrointestinal transcriptional phenotype may be associated with diminished response to AR-targeted therapy.
Subramanian A; Zhang M; Sharifi M; Moreno-Rodriguez T; Feng E; Rydzewski NR; Shrestha R; Zhu X; Zhao SG; Aggarwal R; Small EJ; Ding CC; Quigley DA; Sjöström M
bioRxiv; 2024 Jun; ():. PubMed ID: 38895460
[TBL] [Abstract][Full Text] [Related]
9. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer.
Labrecque MP; Coleman IM; Brown LG; True LD; Kollath L; Lakely B; Nguyen HM; Yang YC; da Costa RMG; Kaipainen A; Coleman R; Higano CS; Yu EY; Cheng HH; Mostaghel EA; Montgomery B; Schweizer MT; Hsieh AC; Lin DW; Corey E; Nelson PS; Morrissey C
J Clin Invest; 2019 Jul; 129(10):4492-4505. PubMed ID: 31361600
[TBL] [Abstract][Full Text] [Related]
10. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
[TBL] [Abstract][Full Text] [Related]
11. Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer.
To SQ; Kwan EM; Fettke HC; Mant A; Docanto MM; Martelotto L; Bukczynska P; Ng N; Graham LK; Parente P; Pezaro C; Mahon K; Horvath L; Todenhöfer T; Azad AA
Eur Urol; 2018 Jun; 73(6):818-821. PubMed ID: 29398263
[TBL] [Abstract][Full Text] [Related]
12. Identification of SPP1 as an Extracellular Matrix Signature for Metastatic Castration-Resistant Prostate Cancer.
Pang X; Xie R; Zhang Z; Liu Q; Wu S; Cui Y
Front Oncol; 2019; 9():924. PubMed ID: 31620371
[TBL] [Abstract][Full Text] [Related]
13. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
14. Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.
Isaacsson Velho P; Fu W; Wang H; Mirkheshti N; Qazi F; Lima FAS; Shaukat F; Carducci MA; Denmeade SR; Paller CJ; Markowski MC; Marshall CH; Eisenberger MA; Antonarakis ES
Eur Urol; 2020 Jan; 77(1):14-21. PubMed ID: 31176623
[TBL] [Abstract][Full Text] [Related]
15. Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer.
Feng E; Rydzewski NR; Zhang M; Lundberg A; Bootsma M; Helzer KT; Lang JM; Aggarwal R; Small EJ; Quigley DA; Sjöström M; Zhao SG
Clin Cancer Res; 2022 Dec; 28(24):5396-5404. PubMed ID: 36260524
[TBL] [Abstract][Full Text] [Related]
16. Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.
Herberts C; Murtha AJ; Fu S; Wang G; Schönlau E; Xue H; Lin D; Gleave A; Yip S; Angeles A; Hotte S; Tran B; North S; Taavitsainen S; Beja K; Vandekerkhove G; Ritch E; Warner E; Saad F; Iqbal N; Nykter M; Gleave ME; Wang Y; Annala M; Chi KN; Wyatt AW
Eur Urol; 2020 Dec; 78(6):834-844. PubMed ID: 32451180
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.
Sharp A; Coleman I; Yuan W; Sprenger C; Dolling D; Rodrigues DN; Russo JW; Figueiredo I; Bertan C; Seed G; Riisnaes R; Uo T; Neeb A; Welti J; Morrissey C; Carreira S; Luo J; Nelson PS; Balk SP; True LD; de Bono JS; Plymate SR
J Clin Invest; 2019 Jan; 129(1):192-208. PubMed ID: 30334814
[TBL] [Abstract][Full Text] [Related]
18. The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer.
Wall JA; Klempner SJ; Arend RC
Expert Opin Investig Drugs; 2020 Jul; 29(7):639-644. PubMed ID: 32408777
[TBL] [Abstract][Full Text] [Related]
19. Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a
Spratt DE; Alshalalfa M; Fishbane N; Weiner AB; Mehra R; Mahal BA; Lehrer J; Liu Y; Zhao SG; Speers C; Morgan TM; Dicker AP; Freedland SJ; Karnes RJ; Weinmann S; Davicioni E; Ross AE; Den RB; Nguyen PL; Feng FY; Lotan TL; Chinnaiyan AM; Schaeffer EM
Clin Cancer Res; 2019 Nov; 25(22):6721-6730. PubMed ID: 31515456
[TBL] [Abstract][Full Text] [Related]
20. ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer.
Lev A; Lulla AR; Ross BC; Ralff MD; Makhov PB; Dicker DT; El-Deiry WS
Mol Cancer Res; 2018 May; 16(5):754-766. PubMed ID: 29588330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
